✦ LIBER ✦

Mortality in DATATOP: A Multicenter trial in early Parkinson's disease

✍ Scribed by Dr Shoulson

Publisher: John Wiley and Sons
Year: 1998
Tongue: English
Weight: 743 KB
Volume: 43
Category: Article
ISSN: 0364-5134
DOI: 10.1002/ana.410430309

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Malignant melanoma in early Parkinson's

Malignant melanoma in early Parkinson's disease: The DATATOP trial

✍ Radu Constantinescu; Megan Romer; Karl Kieburtz 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 53 KB

## Abstract The available epidemiological data on the incidence of malignant melanoma in Parkinson's disease are contradictory. The role of levodopa therapy in this context has been debated. We identified all known cases of malignant melanoma (N = 5) in the DATATOP clinical trial cohort and compare

Test–Retest reliability of the Unified P

Test–Retest reliability of the Unified Parkinson's Disease Rating Scale in patients with early Parkinson's disease: Results from a multicenter clinical trial

✍ Andrew Siderowf; Michael McDermott; Karl Kieburtz; Karen Blindauer; Sandra Plumb 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 1 views

Our objective was to assess the test-retest reliability of the Unified Parkinson's Disease Rating Scale (UPDRS). The UPDRS is the most widely used instrument for measuring severity of parkinsonian symptoms in clinical research and in practice. The validity and inter-rater reliability of this scale h

Selegiline and mortality in Parkinson's

Selegiline and mortality in Parkinson's disease

✍ Dr. C. W. Olanow; S. Fahn; J. W. Langston; J. Godbold 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 489 KB 👁 2 views

## Do Other Studies Show Increased Mortality Due to Selegiline? Other than the UK study, no clinical trial to date has shown an increase in mortality in association with the use of selegiline. In the Sindepar study, a cohort of I01 untreated P D patients participated in a 14-month prospective, ran

Predictors of deterioration in health-re

Predictors of deterioration in health-related quality of life in Parkinson's disease: Results from the DATATOP trial

✍ Connie Marras; Michael P. McDermott; Paula A. Rochon; Caroline M. Tanner; Gary N 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 1 views

## Abstract The aim of this study was to investigate factors associated with decline in health‐related quality of life in Parkinson's disease, by a retrospective cohort study from referral centers in Canada and the United States. Subjects were patients with early Parkinson's disease (N = 362) enrol

A randomized, double-blind trial of tran

A randomized, double-blind trial of transcranial electrostimulation in early Parkinson's disease

✍ Holly A. Shill; Sanja Obradov; Yakov Katsnelson; Ray Pizinger 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

## Abstract We studied the effects of noninvasive transcranial electrical stimulation on the motor and psychological symptoms of early Parkinson's disease. Twenty‐three subjects were treated with 10 days of placebo versus active treatment and then followed for 14 weeks. Baseline off medication Unif

Multicenter trial of naloxone in alzheim

Multicenter trial of naloxone in alzheimer's disease

✍ Dr. V. W. Henderson; E. Roberts; C. Wimer; E. L. Bardolph; H. C. Chui; A. R. Dam 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 312 KB 👁 2 views